Abstract: The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention.

Abstract: The invention relates to a method for using a dual-compartment bioreactor that comprises a flexible pouch (1) with two compartments (2, 3) separated by a filter (4), as well as at least one inlet opening (5) in communication with one of the compartments (2) and at least one outlet opening (6) in communication with the other compartment (3), wherein said method comprises the implementation thereof in biological processing equipment particularly for washing or converting a tissue or biological product, characterised in that the method comprises, for a tissue dissociation, using said bioreactor as a digestion chamber and manually kneading the flexible pouch (1) for dissociating the tissues during a digestion step in which a digestion solution containing collagenase flows between the inlet (5) and outlet (6) openings of the pouch.

Abstract: The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention.